Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Clearmind Medicine Inc., a clinical-stage biotech company focused on non-hallucinogenic neuroplastogen-derived therapeutics, announced filing a patent application in Hong Kong for innovative psychedelic compounds aimed at treating PTSD and other mental health disorders. This strengthens the company's global IP portfolio under its exclusive licensin…